Letrozole is also more effective than tamoxifen as a preoperative treatment in postmenopausal patients with ER- and/or Progesterone Receptor (PgR)-positive primary breast cancer, although the response rate of 55% [6] is suboptimal. Here, ESR1 is linked to breast carcinoma.